Acute Monoblastic Leukemia

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Acute Monoblastic Leukemia

MalaCards integrated aliases for Acute Monoblastic Leukemia:

Name: Acute Monoblastic Leukemia 52 6 71
Acute Monocytic Leukemia 52 71
M5b Acute Differentiated Monocytic Leukemia 71
Acute Monocytic/monoblastic Leukemia 71
Acute Myeloblastic Leukemia Type 5 52
Aml M5 52
Aml-M5 52


Summaries for Acute Monoblastic Leukemia

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 514 Definition Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML; see this term) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11). Visit the Orphanet disease page for more resources.

MalaCards based summary : Acute Monoblastic Leukemia, also known as acute monocytic leukemia, is related to leukemia, acute monocytic and acute leukemia. An important gene associated with Acute Monoblastic Leukemia is LPP (LIM Domain Containing Preferred Translocation Partner In Lipoma), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Mesna and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone, and related phenotypes are acute monocytic leukemia and fatigue

Related Diseases for Acute Monoblastic Leukemia

Diseases related to Acute Monoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 270)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute monocytic 32.8 KMT2A IL6 CXCL8
2 acute leukemia 30.5 KMT2A IL7 EPO CSF2
3 monocytic leukemia 30.5 KMT2A IL6 CXCL8 CSF2
4 pancytopenia 30.2 KMT2A IL6 EPO CSF2
5 exanthem 30.2 IL6 CXCL8 CSF2
6 aspergillosis 30.1 IL6 CXCL8 CSF2
7 thrombocytosis 30.0 IL6 EPO CSF2
8 gingival overgrowth 29.9 SOS1 IL6 CXCL8
9 myeloproliferative neoplasm 29.9 NF1 KMT2A EPO CSF2
10 neuroblastoma 29.8 TSC2 SOS1 NF1 IL6 CSF2 CD44
11 neutropenia 29.8 IL6 EPO CXCL8 CSF2
12 juvenile myelomonocytic leukemia 29.6 SOS1 NF1 KMT2A CSF2
13 lung disease 29.6 TSC2 IL6 CXCL8 CSF2 CD44
14 essential thrombocythemia 29.6 IL6 EPO CXCL8 CSF2
15 acute promyelocytic leukemia 29.3 KMT2A IL6 CXCL8 CSF2 CD44
16 leukemia, acute myeloid 29.1 NF1 LPP KMT2A IL7 IL6 EPO
17 myeloma, multiple 29.1 IL7 IL6 EPO CXCL8 CSF2 CD44
18 myelodysplastic syndrome 29.1 NF1 KMT2A IL7 IL6 EPO CXCL8
19 thrombocytopenia 29.1 IL7 IL6 EPO CXCL8 CSF2 CD44
20 leukemia, chronic lymphocytic 29.0 KMT2A IL7 IL6 CSF2 CD44
21 lymphoma, non-hodgkin, familial 28.9 KMT2A IL7 IL6 CSF2 CD44
22 adult acute monocytic leukemia 12.9
23 leukemia 10.9
24 myeloid leukemia 10.6
25 myeloid sarcoma 10.5
26 sarcoma 10.5
27 spindle cell sarcoma 10.5
28 disseminated intravascular coagulation 10.4
29 chromosomal triplication 10.4
30 acute monoblastic/monocytic leukemia 10.4
31 optic nerve astrocytoma 10.4 TSC2 NF1
32 skin granular cell tumor 10.4 SOS1 NF1
33 engraftment syndrome 10.4 CXCL8 CSF2
34 47,xyy 10.4
35 vibrio vulnificus infection 10.3 IL6 EPO
36 idiopathic anterior uveitis 10.3 IL6 CXCL8
37 streptococcal toxic-shock syndrome 10.3 IL6 CXCL8
38 acute transverse myelitis 10.3 IL6 CXCL8
39 transverse myelitis 10.3 IL6 CXCL8
40 anemia of prematurity 10.3 EPO CSF2
41 fuchs' heterochromic uveitis 10.3 IL6 CXCL8
42 leukemia, acute lymphoblastic 10.3
43 histiocytosis 10.3
44 ceftazidime allergy 10.2 IL7 EPO
45 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.2 EPO CSF2
46 b-cell growth factor 10.2 IL7 IL6
47 spinal cord disease 10.2 TSC2 NF1 IL6
48 lichen disease 10.2 LPP IL6 CXCL8
49 neuroma 10.2 SOS1 NF1 IL6
50 chronic myelomonocytic leukemia 10.2

Graphical network of the top 20 diseases related to Acute Monoblastic Leukemia:

Diseases related to Acute Monoblastic Leukemia

Symptoms & Phenotypes for Acute Monoblastic Leukemia

Human phenotypes related to Acute Monoblastic Leukemia:

31 (show all 17)
# Description HPO Frequency HPO Source Accession
1 acute monocytic leukemia 31 obligate (100%) HP:0004845
2 fatigue 31 frequent (33%) HP:0012378
3 exertional dyspnea 31 frequent (33%) HP:0002875
4 lymphocytosis 31 frequent (33%) HP:0100827
5 bone marrow hypercellularity 31 frequent (33%) HP:0031020
6 fever 31 occasional (7.5%) HP:0001945
7 weight loss 31 occasional (7.5%) HP:0001824
8 subcutaneous nodule 31 occasional (7.5%) HP:0001482
9 anorexia 31 occasional (7.5%) HP:0002039
10 periorbital edema 31 occasional (7.5%) HP:0100539
11 progressive hearing impairment 31 occasional (7.5%) HP:0001730
12 oliguria 31 occasional (7.5%) HP:0100520
13 cervical lymphadenopathy 31 occasional (7.5%) HP:0025289
14 hypochromic anemia 31 occasional (7.5%) HP:0001931
15 central hypothyroidism 31 occasional (7.5%) HP:0011787
16 ankle swelling 31 occasional (7.5%) HP:0001785
17 increased lactate dehydrogenase level 31 occasional (7.5%) HP:0025435

MGI Mouse Phenotypes related to Acute Monoblastic Leukemia:

# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 CD44 CSF2 EPO GPHN IL6 KMT2A
2 cardiovascular system MP:0005385 10.11 CD44 CSF2 EPO IL6 KMT2A NF1
3 hematopoietic system MP:0005397 10.1 CD44 CSF2 EPO IL6 IL7 KMT2A
4 integument MP:0010771 10.02 CD44 CSF2 EPO IL6 KMT2A NF1
5 liver/biliary system MP:0005370 9.87 CD44 EPO IL6 KMT2A NF1 STK11
6 muscle MP:0005369 9.8 CD44 EPO IL6 KMT2A NF1 SOS1
7 neoplasm MP:0002006 9.7 CD44 CSF2 IL6 KMT2A NF1 STK11
8 renal/urinary system MP:0005367 9.5 CD44 CSF2 IL6 KMT2A NF1 STK11
9 respiratory system MP:0005388 9.17 CD44 CSF2 EPO GPHN IL6 NF1

Drugs & Therapeutics for Acute Monoblastic Leukemia

Drugs for Acute Monoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Mesna Approved, Investigational Phase 3 3375-50-6 598
Idarubicin Approved Phase 3 58957-92-9 42890
leucovorin Approved Phase 3 58-05-9 6006 143
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
Lenograstim Approved, Investigational Phase 3 135968-09-1
Etoposide Approved Phase 3 33419-42-0 36462
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
Thioguanine Approved Phase 3 154-42-7 2723601
Melphalan Approved Phase 3 148-82-3 460612 4053
Carmustine Approved, Investigational Phase 3 154-93-8 2578
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
Hydroxyurea Approved Phase 3 127-07-1 3657
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
Daunorubicin Approved Phase 3 20830-81-3 30323
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
Histamine Approved, Investigational Phase 3 51-45-6 774
Cyproheptadine Approved Phase 3 129-03-3 2913
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
32 Lintuzumab Investigational Phase 3 166089-32-3
33 Molgramostim Investigational Phase 3 99283-10-0
tipifarnib Investigational Phase 2, Phase 3 192185-72-1 159324
35 Vaccines Phase 3
36 Immunoglobulins Phase 3
37 Antibodies Phase 3
38 Antibodies, Monoclonal Phase 3
39 Gemtuzumab Phase 3
40 Antineoplastic Agents, Immunological Phase 3
41 Folic Acid Antagonists Phase 3
42 Vitamin B Complex Phase 3
43 Folate Phase 3
44 Antirheumatic Agents Phase 3
45 Vitamin B9 Phase 3
46 Etoposide phosphate Phase 3
47 Protective Agents Phase 3
48 Radiation-Protective Agents Phase 3
49 Analgesics Phase 3
50 Adjuvants, Immunologic Phase 3

Interventional clinical trials:

(show top 50) (show all 110)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
2 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
4 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
5 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
6 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
8 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
9 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
10 High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
12 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
13 Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
14 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
15 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
16 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
17 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
18 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
19 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
20 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
22 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
23 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
24 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
25 Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 Unknown status NCT00006084 Phase 2
26 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
27 Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial) Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
28 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
29 Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML) Completed NCT00528398 Phase 2 cytarabine;idarubicin
30 Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old Completed NCT00005795 Phase 2 arsenic trioxide
32 5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial. Completed NCT00739388 Phase 2 azacytidine
33 A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT01656031 Phase 2 clofarabine;cytarabine
34 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene
35 A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60 Completed NCT00089050 Phase 2 cyclosporine;gemtuzumab ozogamicin
36 Pilot Study of Sodium Phenylbutyrate Plus Azacytidine Completed NCT00006019 Phase 2 azacitidine;sodium phenylbutyrate
37 A Phase II Study of Allografting to Establish Mixed or Full Donor Chimerism as Consolidative Immunotherapy for Older Patients With AML in Complete Remission Using Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00005801 Phase 2
38 Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
39 A Phase II Study Of Daunomycin And ARA-C, Both Given By Continous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older Completed NCT00023777 Phase 2 cytarabine;daunorubicin hydrochloride
40 Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study Completed NCT00003178 Phase 2 cladribine;idarubicin
41 A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML) Completed NCT00049179 Phase 2 cytarabine;gemtuzumab ozogamicin
42 A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
43 Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
44 ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
45 An Open Label Phase II Trial of Clofarabine and Temsirolimus in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Completed NCT00775593 Phase 2 clofarabine;temsirolimus
46 Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study Completed NCT00006122 Phase 2 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
47 A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia Completed NCT00005962 Phase 2 cyclophosphamide;cytarabine;gemtuzumab ozogamicin;liposomal daunorubicin citrate;topotecan hydrochloride
48 A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide (DATE) for De Novo AML: In the Treatment of Young Patients Ages 16-59 Completed NCT00005793 Phase 1, Phase 2 Cytarabine;Daunorubicin;Etoposide;Topotecan
49 A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older Completed NCT00004217 Phase 2 cytarabine;daunorubicin hydrochloride;valspodar
50 Clinical Protocol for a Phase II Study of Leridistim (SC-70935) in Adult Patients (Age>55) With Acute Myeloid Leukemia (AML) Receiving Chemotherapy With the Cytarabine and Daunorubicin "7+3" Regimen Completed NCT00004215 Phase 2 cytarabine;daunorubicin hydrochloride

Search NIH Clinical Center for Acute Monoblastic Leukemia

Genetic Tests for Acute Monoblastic Leukemia

Anatomical Context for Acute Monoblastic Leukemia

MalaCards organs/tissues related to Acute Monoblastic Leukemia:

Monocytes, Myeloid, Bone, Bone Marrow, T Cells, Skin, Endothelial

Publications for Acute Monoblastic Leukemia

Articles related to Acute Monoblastic Leukemia:

(show top 50) (show all 1210)
# Title Authors PMID Year
Identification of a t(X;17)(q28;q21) generating a KANSL1-MTCP1 gene fusion leading to dysregulated expression of MTCP1 in acute myeloid leukemia. 61
32167630 2020
Widespread Skin Infiltration of Leukemia Cutis on 18F-FDG PET/CT. 61
32558715 2020
Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia. 61
32216042 2020
PFKFB4 is critical for the survival of acute monocytic leukemia cells. 61
32299611 2020
CD47 decline in pancreatic islet cells promotes macrophage-mediated phagocytosis in type I diabetes. 61
32547698 2020
[Clinical Characteristics and Prognostic Influencing Factors of Adult AML Patients with MLL Rearrangement]. 61
32552935 2020
Acute Monoblastic Leukemia with Erythrophagocytosis and Absence of KAT6A Rearrangement. 61
32519830 2020
Triiodothyronine Attenuates Silica-Induced Oxidative Stress, Inflammation, and Apoptosis via Thyroid Hormone Receptor α in Differentiated THP-1 Macrophages. 61
32223187 2020
Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations. 61
32443883 2020
Distinct anti-proliferative effects of herbal melanin on human acute monocytic leukemia THP-1 cells and embryonic kidney HEK293 cells. 61
32448225 2020
Acute monoblastic leukemia in a feline leukemia virus-negative cat. 61
32448817 2020
Cytotoxic and antiproliferative activities of amphibian (anuran) skin extracts on human acute monocytic leukemia cells. 61
31982457 2020
Identification and functional study of immortalized mouse thymic epithelial cells. 61
32107001 2020
The P2X7 receptor mediates NLRP3-dependent IL-1β secretion and promotes phagocytosis in the macrophage response to Treponema pallidum. 61
32151957 2020
GP73 facilitates hepatitis B virus replication by repressing the NF-κB signaling pathway. 61
32077512 2020
Transient Receptor Potential Ankyrin 1 Contributes to Lysophosphatidylcholine-Induced Intracellular Calcium Regulation and THP-1-Derived Macrophage Activation. 61
31820013 2020
Endometrial stromal cells treated by tumor necrosis factor-α stimulate macrophages polarized toward M2 via interleukin-6 and monocyte chemoattractant protein-1. 61
31930665 2020
Effects of green tea epigallocatechin-3-gallate on transcription factors regulating expression of FLT3. 61
32277682 2020
LINC00449 regulates the proliferation and invasion of acute monocytic leukemia and predicts favorable prognosis. 61
31960456 2020
Anisotropic Platinum Nanoparticle-Induced Cytotoxicity, Apoptosis, Inflammatory Response, and Transcriptomic and Molecular Pathways in Human Acute Monocytic Leukemia Cells. 61
31936679 2020
JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review. 61
32042586 2020
[Pulmonary infiltration of acute monoblastic leukemia diagnosed by transbronchial lung biopsy]. 61
32023598 2020
Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion. 61
31701557 2019
Development of myelofibrosis and acute monocytic leukemia in a patient with hereditary spherocytosis: A case report. 61
31852097 2019
D-4F, an apolipoprotein A-I mimetic, suppresses IL-4 induced macrophage alternative activation and pro-fibrotic TGF-β1 expression. 61
31335245 2019
[Inhibitory Effect of Eukaryotic Expression Vector Bearing TFPI-2 Gene on SHI-1 Cell Growth]. 61
31839043 2019
MicroRNA‑20a negatively regulates the growth and osteoclastogenesis of THP‑1 cells by downregulating PPARγ. 61
31545439 2019
Red blood cells participate in reverse cholesterol transport by mediating cholesterol efflux of high-density lipoprotein and apolipoprotein A-I from THP-1 macrophages. 61
31188743 2019
Antileukemic activity of novel adenosine derivatives. 61
31575977 2019
Molecular hydrogen suppresses free-radical-induced cell death by mitigating fatty acid peroxidation and mitochondrial dysfunction. 61
31295412 2019
The effects of photodynamic therapy on leukemia cells mediated by KillerRed, a genetically encoded fluorescent protein photosensitizer. 61
31590660 2019
[Regulatorg Mchanism of MiR-152 on Proliferation, Metastasis and Tumorigenicity of SHI-1 Cells]. 61
31607298 2019
Characteristic genes in THP‑1 derived macrophages infected with Mycobacterium tuberculosis H37Rv strain identified by integrating bioinformatics methods. 61
31364746 2019
MicroRNA‑217 is involved in the progression of atherosclerosis through regulating inflammatory responses by targeting sirtuin 1. 61
31432137 2019
[Effects of Transcription Factor MZF-1 on Transcriptive Regulation of Acute Monocytic Leukemia-related Gene MLAA-34]. 61
31607299 2019
Pd(II) complexes with N-heteroaromatic hydrazone ligands: Anticancer activity, in silico and experimental target identification. 61
31299379 2019
Priming with GM-CSF instead of G-CSF enhances CAG-induced apoptosis of acute monocytic leukemia cells in vitro. 61
31115604 2019
Cytogenetics and associated mutation profile in patients with acute monocytic leukemia. 61
31099482 2019
[The value of detecting MLL gene rearrangement in children with acute monocytic leukemia]. 61
31400126 2019
Making it stick: A CURE designed to introduce students to the scientific process and the host response to foreign materials. 61
31002463 2019
[Characterizing the molecular cytogenetics in acute monocytic leukemia]. 61
31055804 2019
[Cloning of New Antigen Gene MLAA-34 Promoter and Identification of Core Region in Acute Monocytic Leukemia]. 61
31204911 2019
Eutopic endometrium from patients with endometriosis modulates the expression of CD36 and SIRP-α in peritoneal macrophages. 61
30843336 2019
Morus alba Stem Extract Suppresses Matrix Metalloproteinases (MMP)-1, MMP-9, and Tissue Inhibitors of Metalloproteinase (TIMP)-1 Expression via Inhibition of IκBα Degradation Induced by Porphyromonas gingivalis LPS Signal in THP-1 Cells. 61
31569263 2019
Extracellular Vesicles from Interferon-γ-primed Human Umbilical Cord Mesenchymal Stromal Cells Reduce Escherichia coli-induced Acute Lung Injury in Rats. 61
30870158 2019
Ets1 Plays a Critical Role in MLL/EB1-Mediated Leukemic Transformation in a Mouse Bone Marrow Transplantation Model. 61
30974389 2019
Albiflorin inhibits the formation of THP-1-derived foam cells through the LOX-1/NF-κB pathway. 61
30371044 2019
Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report. 61
30885156 2019
HMGB1 from Lampetra japonica promotes inflammatory activation in supraneural body cells. 61
30423344 2019
Non-acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17). 61
30899494 2019

Variations for Acute Monoblastic Leukemia

ClinVar genetic disease variations for Acute Monoblastic Leukemia:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STK11 NM_000455.4(STK11):c.970C>G (p.Pro324Ala)SNV Conflicting interpretations of pathogenicity 127710 rs549474196 19:1223033-1223033 19:1223034-1223034
2 NF1 NM_000267.3(NF1):c.1588G>A (p.Val530Ile)SNV Conflicting interpretations of pathogenicity 141369 rs145191978 17:29546083-29546083 17:31219065-31219065
3 NF1 NM_000267.3(NF1):c.2747A>G (p.Asn916Ser)SNV Uncertain significance 229977 rs765043916 17:29556380-29556380 17:31229362-31229362
4 TSC2 NM_000548.5(TSC2):c.5336A>G (p.Gln1779Arg)SNV Benign/Likely benign 514715 rs748947919 16:2138523-2138523 16:2088522-2088522
5 SOS1 NM_005633.3(SOS1):c.2371C>A (p.Leu791Ile)SNV Benign 40702 rs142004123 2:39239286-39239286 2:39012145-39012145

Expression for Acute Monoblastic Leukemia

Search GEO for disease gene expression data for Acute Monoblastic Leukemia.

Pathways for Acute Monoblastic Leukemia

Pathways related to Acute Monoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
Show member pathways
13.68 TSC2 STK11 SOS1 NF1 IL7 IL6
Show member pathways
13.18 SOS1 NF1 IL7 IL6 CXCL8 CSF2
Show member pathways
12.79 TSC2 SOS1 IL6 CXCL8 CSF2
Show member pathways
12.75 TSC2 STK11 SOS1 IL7 IL6 EPO
5 12.68 SOS1 IL7 IL6 EPO CXCL8
Show member pathways
12.2 SOS1 IL7 IL6 EPO CSF2
7 12.09 KMT2A IL6 CXCL8 CSF2
8 11.83 TSC2 SOS1 NF1
9 11.78 IL6 CXCL8 CSF2
10 11.73 IL6 CXCL8 CSF2
Show member pathways
11.72 IL6 CXCL8 CSF2
12 11.66 IL6 CXCL8 CSF2
13 11.58 KMT2A IL6 CXCL8 CD44
Show member pathways
11.52 IL6 CXCL8 CSF2
15 11.51 IL6 CXCL8 CSF2
16 11.42 IL7 IL6 EPO CSF2 CD44
17 11.41 NF1 IL6 CXCL8
18 11.34 IL6 CXCL8 CSF2
19 11.31 IL6 EPO CSF2
20 11.16 SOS1 IL6 CXCL8 CD44
21 11.06 NF1 CXCL8 CSF2
22 11.02 IL7 IL6 EPO CSF2 CD44
23 10.96 IL7 IL6 CSF2

GO Terms for Acute Monoblastic Leukemia

Biological processes related to Acute Monoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.35 TSC2 STK11 NF1 IL6 CXCL8
2 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.33 IL6 EPO CSF2
3 anoikis GO:0043276 9.26 TSC2 STK11
4 cytokine-mediated signaling pathway GO:0019221 9.02 SOS1 IL7 IL6 CXCL8 CSF2

Molecular functions related to Acute Monoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 IL7 IL6 EPO CXCL8 CSF2

Sources for Acute Monoblastic Leukemia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....